Are drug-price guarantees here to stay?
PHARMACY BENEFIT CONTRACTS provide a range of value propositions. While drug-pricing pass-through arrangements ensure that health-plan sponsors are invoiced what the pharmacy benefit manager (PBM) actually pays the pharmacy-dollar for dollar-drug-price guarantees provide similar assurances on cost.
Buscetto defines a drug price guarantee as "the guaranteed rate off any nationally recognized drug compendium for both branded and generic drugs over a retrospective, versus a prospective, period of time for the same members."
Randy Vogenberg, principal, Institute for Integrated Healthcare (IIH), Sharon, Mass., says price guarantees are not necessary if a PBM manages the drug spend effectively. He believes that guarantees work best when managing the benefit for smaller employers, whose costs are easier to control, thus reducing risk.
PAYERS SEEKING GOOD DEALS
Although drug price guarantees are rather new to the PBM/payer relationship, drug manufacturers already use alternative pricing programs with payers, sharing risk and agreeing to certain price protections, often based on drug performance or utilization. For example, CIGNA has two outcomes-based contracts, one with Merck for its Januvia and Janumet drugs for diabetes, and the other with EMD Serona for its multiple sclerosis drug, Rebif.
PBMs such as Prime Therapeutics, Humana Pharmacy Solutions and Us-Rx Care have developed their own programs for payers-assuming risk and aligning goals. Analyzing prior year drug costs, providing dollar-for-dollar assurances and developing an agreed-upon formulary are integral elements of such price guarantees.
Buscetto says that SXC looks at drug spend by a payer for the preceding year and takes drug price points, dispensing fees and rebates into consideration before settling on the amount of the guarantee it would offer. The PBM shares savings with its clients for every dollar that is saved below the guarantee.
Patients Express Concerns Over Costs, Risks of Gene Therapies for Sickle Cell Disease
December 12th 2024Research at the annual meeting of the American Society of Hematology evaluated patient and caregiver perspectives on gene therapies for sickle cell disease, which offer great potential but have had slow uptake.
Read More
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen